Trial Profile

A Phase 1b/2a Study of PU-AD in Alzheimer's Patients

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Icapamespib (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Therapeutic Use
Sponsors Samus Therapeutics

Most Recent Events

26 Jul 2019 New trial record
23 Jul 2019 According to a Samus Therapeutics media release, assuming the expeditious completion of the phase I study (NCT03935568), the Company would begin PU-AD clinical testing of Alzheimer's patients in this phase1b/2a in the first half of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com